alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › faers

faers

4 studies tagged faers, dated 2026-06-22 to 2026-10-02. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Safety of lecanemab in real-world patients with Alzheimer's disease: a prospective, observational case series supported by FAERS signal analysis 2026-10-02
  2. Disproportionality analysis of adverse event signals associated with seven Alzheimer's drugs: insights from the FAERS database 2026-09-24
  3. Post-marketing safety signals and report-level ARIA-E stratification for lecanemab and donanemab: an integrated FAERS and WHO-VigiAccess pharmacovigilance study 2026-08-18

Studies

4 studies carry this tag.

Date range

2026

Top journals

  • Frontiers in neuroinformatics 1
  • Frontiers in pharmacology 1
  • Frontiers in psychiatry 1
  • Therapeutic advances in drug safety 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Safety of lecanemab in real-world patients with Alzheimer's disease: a prospective, observational case series supported by FAERS signal analysis

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Frontiers in neuroinformatics 2026-10-02 Treatments

    Although clinical trials have demonstrated its favorable safety profile, real-world studies are crucial for identifying rare adverse events (AEs) and evaluating post-marketing safety.

  2. Disproportionality analysis of adverse event signals associated with seven Alzheimer's drugs: insights from the FAERS database

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Frontiers in pharmacology 2026-09-24 Treatments

    This study utilized FAERS data to compare adverse event reporting signals for seven anti-AD drugs.

  3. Post-marketing safety signals and report-level ARIA-E stratification for lecanemab and donanemab: an integrated FAERS and WHO-VigiAccess pharmacovigilance study

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Therapeutic advances in drug safety 2026-08-18 Treatments

    FAERS included 2961 lecanemab and 1542 donanemab primary suspect reports; WHO-VigiAccess included 2525 lecanemab- and 1450 donanemab-related reports.

  4. Post-marketing safety of lecanemab: a real-world study based on FAERS database, multicenter cohort and network pharmacology

    ✓ Peer-reviewed alzhub usefulness score 66 out of 100. Frontiers in psychiatry 2026-06-22 Treatments

    This study provides real-world evidence on the risk profile of lecanemab, highlighting the importance of continued safety monitoring.

All topic tags with their study counts